On July 21st, 2017, H.E. the United States Ambassador to Greece Mr. Geoffrey Pyatt visited the Laboratory of Molecular Biology and Immunology, University of Patras (UPAT), as part of his visit to academic entities in Patras that produce and offer innovative results and services in the biotechnology and healthcare sectors.
The 2nd UPGx Personalized Medicine Day will be organized in Vienna, Austria on Friday May 12th, 2017. The meeting will be organized at the Medical University of Vienna and will follow the 2nd Consortium Meeting of the UPGx project that will be held May 10-11, 2017. Continue reading
Despite scientific and clinical advances in the field of pharmacogenomics (PGx), application into routine care remains limited. Opportunely, several implementation studies and programmes have been initiated over recent years. This article presents an overview of these studies and identifies current research gaps. Continue reading
The 1st UPGx Personalized Medicine Day, the first of a series of dissemination events for healthcare professionals and biomedical scientists that will be organized by the UPGx project, has been successfully held on Thursday December 1st, 2016 in Granada, Spain. Continue reading
The 2016 Golden Helix Summer School with the theme “Cancer Genomics and Individualized Therapy” was successfully organized at the Dolphin Bay Resort hotel in Syros island, Greece, 22-26 September 2016. Continue reading
This U-PGx video visualises and promotes the idea of personalised medicine and pre-emptive PGx testing. The video can be be used to inform the public via the webpage, for educational purpose and for communication with stakeholders and at (inter)national workshops. Continue reading
The study reported by Kapoor et al in this month’s European Journal of Human Genetics explains the dichotomy between the accelerated pace of discovery and the slow uptake of pharmacogenomics in standard clinical care through a SWOT analysis. A glass can be perceived as being half-full or half-empty. Continue reading
David Haerry is a patients’ advocate. He is a member of the European AIDS Treatment Group (EATG). David has been involved in HIV drug development for many years and has specific interests in the areas of Personalised Medicine, Risk Communication and Doctor/Patient Communication, Pharmacovigilance, Observational Studies, Biomedical Prevention and HIV Eradication Research.